Pharmaceuticals

A 2025 Phase 2 trial of eloralintide (manufactured by Eli Lilly) in 263 adults with overweight or obesity but without diabetes found that after 48 weeks participants lost between 9.5% and 20.1% of body weight versus 0.4% for placebo, and the treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation, with up to 90% of participants improving by at least one BMI category.

GLP-1 receptor agonist medications (examples include semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro, and other agents such as Zepbound) mimic the gut hormone glucagon-like peptide-1 (GLP-1) and act by slowing digestion, reducing appetite, and helping to control blood sugar after meals.

In the 2025 Phase 2 trial of eloralintide, the most commonly reported adverse effects were mild-to-moderate gastrointestinal symptoms and fatigue, and these adverse effects were more frequent or severe at higher doses.

Gonal-f is a fertility drug marketed by EMD Serono that is used to treat infertility in women and men.

Lenacapavir is a long-acting injectable drug developed and manufactured by Gilead Sciences for HIV prevention.

Eloralintide is a selective amylin receptor agonist that mimics the pancreatic hormone amylin and is intended to slow gastric emptying, reduce appetite, and help control postprandial blood glucose; this mechanism differs from GLP-1 receptor agonists, which mimic the gut hormone GLP-1.